New sinusoidal pump for transferring syrups, oils, creams and gels
Watson-Marlow's new Certa Plus sinusoidal pump provides a sustainable solution for shear sensitive, viscous pharmaceutical products.
Watson-Marlow Fluid Technology Group has launched its new Certa Plus pump series to provide sustainable, high-quality, versatile fluid management for the pharmaceutical industry.
Compared with conventional lobe pumps, the new sinusoidal Certa Plus technology offers pharmaceutical manufacturers lower shear, lower power consumption, full traceability, and ultimate cleanability when transferring syrups, oils, creams and gels.
Certa Plus provides virtually pulsation-free product flow with no need for ancillary dampeners. This improves both flow meter accuracy and heat exchanger efficiency. The low shear handling minimises the temperature increase of the pumped liquid, as well as improving batch consistency and final product quality.
The new pump series is capable of transferring and handling a wide range of challenging products from syrups and sugar solutions to lozenge products.
Its continuous flow and high suction support the efficient manufacture of pastille products. Syrup and sugar solutions can also be processed with ease as the seal flush reduces the risk of sugar-based products drying out at the seal.
Across pharmaceutical applications, varying temperatures result in products with varying viscosities. For example, in the production of suppositories, pumping at lower temperature means an increased viscosity of the product. The powerful suction of the Certa Plus handles both low viscous liquids such as oils, and high viscous products, such as creams and gels, with ease.
Clean in place capabilities enable ease of cleaning and allow the pump to be easily integrated into an aseptic fluid path. The pump can then be wet cleaned without dismantling and is steam sterilisable and bacteria-tight to remove the risk of residuals and contamination. Certa Plus has full aseptic certification (EHEDG Type EL Class I and EHEDG Type EL Aseptic Class I) and all components are made of FDA and USP Class VI certified raw materials.
The pump also offers an energy-efficient alternative, requiring up to 50% less power than lobe or circumferential piston pumps, greatly reducing electricity use and hence carbon footprint.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.